<![CDATA[All-Oral Decitabine/Cedazuridine Combo Enters Frontline AML]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>

<![CDATA[Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma]]>

<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>

Epigenomic Analysis Reveals 16 New AML Subgroups and Drug Sensitivities

A chromatin-based study of 1,563 AML samples identifies novel epigenomic subgroups that enhance prognostic accuracy and uncover unexpected t

Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse

Conditions : Acute Myeloid Leukemia (AML); Maintenance Treatment; Hematopoetic Stem Cell Transplantation Interventions : Drug: Lisaftoclax P